Skandinaviska Enskilda Banken (SEB)’s PTC Therapeutics PTCT Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-35,945	Closed	-$991K	–	917
2023 Q4	$991K	Hold	35,945	–	–	0.01%	698
2023 Q3	$806K	Hold	35,945	–	–	0.01%	709
2023 Q2	$1.46M	Hold	35,945	–	–	0.01%	629
2023 Q1	$1.74M	Sell	35,945 -1,731	-5%	-$79.1K	0.01%	583
2022 Q4	$1.44M	Sell	37,676 -2,183	-5%	-$90.8K	0.01%	602
2022 Q3	$2M	Hold	39,859	–	–	0.02%	543
2022 Q2	$1.6M	Hold	39,859	–	–	0.01%	627
2022 Q1	$1.49M	Hold	39,859	–	–	0.01%	679
2021 Q4	$1.6M	Hold	39,859	–	–	0.01%	697
2021 Q3	$1.48M	Hold	39,859	–	–	0.01%	720
2021 Q2	$1.69M	Buy	39,859 +10,284	+35%	+$441K	0.01%	711
2021 Q1	$1.4M	Buy	+29,575	New	+$1.76M	0.01%	752

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s PTCT Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of PTC Therapeutics (PTCT) in Q1 2024, closing a stake of 35,945 shares — an estimated $991K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in PTCT in Q1 2021 and held it in 12 quarters. The position peaked at $2M in Q3 2022. 184 funds tracked by Wall St. Rank hold PTCT as of Q1 2024.

Skandinaviska Enskilda Banken (SEB) reported no remaining PTC Therapeutics position as of Q1 2024 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 35,945 PTC Therapeutics shares in Q1 2024, an estimated $991K.
Skandinaviska Enskilda Banken (SEB) first reported a position in PTC Therapeutics in Q1 2021 and held it in 12 quarters.
Skandinaviska Enskilda Banken (SEB)'s PTC Therapeutics position peaked at $2M in Q3 2022.
184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.